Alpha 2.0
Login Register
» Articles » PMID: 25541606

Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?

Overview
Journal Diabetes Metab J
Specialty Endocrinology
Date 2014 Dec 27
PMID 25541606
Citations 5
Authors
Kyu Yeon Hur
Affiliations
Soon will be listed here.
Citing Articles

Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis: A pilot study.

Song Y, Cui Y, Zhang X, Lin H, Zhang G, Zeng H Medicine (Baltimore). 2018; 97(51):e13733.

PMID: 30572513 PMC: 6320148. DOI: 10.1097/MD.0000000000013733.

Multi-omic analysis of signalling factors in inflammatory comorbidities.

Xiao H, Bartoszek K, Lio P BMC Bioinformatics. 2018; 19(Suppl 15):439.

PMID: 30497370 PMC: 6266935. DOI: 10.1186/s12859-018-2413-x.

Mechanisms regulating intestinal barrier integrity and its pathological implications.

Chelakkot C, Ghim J, Ryu S Exp Mol Med. 2018; 50(8):1-9.

PMID: 30115904 PMC: 6095905. DOI: 10.1038/s12276-018-0126-x.

Response: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J 2014;38:472-9).

Hong J, Ku B, Shong M Diabetes Metab J. 2015; 39(1):84-6.

PMID: 25729718 PMC: 4342542. DOI: 10.4093/dmj.2015.39.1.84.

Letter: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J 2014;38:472-9).

Koo B Diabetes Metab J. 2015; 39(1):82-3.

PMID: 25729717 PMC: 4342541. DOI: 10.4093/dmj.2015.39.1.82.

References
1.
Hong J, Chung H, Park H, Joung K, Lee J, Jung J . GDF15 Is a Novel Biomarker for Impaired Fasting Glucose. Diabetes Metab J. 2014; 38(6):472-9. PMC: 4273034. DOI: 10.4093/dmj.2014.38.6.472. View
2.
Kempf T, Guba-Quint A, Torgerson J, Magnone M, Haefliger C, Bobadilla M . Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol. 2012; 167(5):671-8. DOI: 10.1530/EJE-12-0466. View
3.
Baek S, Kim K, Nixon J, Wilson L, Eling T . Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol. 2001; 59(4):901-8. View
4.
Carstensen M, Herder C, Brunner E, Strassburger K, Tabak A, Roden M . Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol. 2010; 162(5):913-7. DOI: 10.1530/EJE-09-1066. View
5.
Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P . Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2008; 150(4):1688-96. DOI: 10.1210/en.2008-0952. View